HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $50 price target.
August 10, 2023 | 11:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics (NASDAQ:PLRX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $50.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for Pliant Therapeutics. The maintained price target of $50 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100